Table 3.
Survivorship of different UKA designs
| UKA design | Years | Number* | Mean followup years/(range) | At 5 years** (95% CI) | At 10 years** (95% CI) | At 15 years** (95% CI) | HR (95% CI) | p value |
|---|---|---|---|---|---|---|---|---|
| Oxford® | 1990–2011 | 439/4084 | 5.2 (0–21) | 90.4 (89.4,91.3) | 83.7 (82.5,84.8) | 76.9 (75.6,78.2) | 1.0 | – |
| Miller-Galante | 1990–2005 | 90/318 | 11.3 (1–21) | 89.1 (85.0,92.2) | 77.4 (72.4,81.8) | 66.7 (63.7,74.1) | 1.2 (0.9–1.5) | 0.19 |
| Duracon™ | 1993–2000 | 39/140 | 10.5 (0–19) | 84.8 (77.6,90.1) | 76.7 (68.7,83.3) | 70.7 (62.3,77.9) | 1.2 (0.9–1.7) | 0.29 |
| PCA® | 1985–1995 | 95/171 | 9.5 (1–24) | 75.7 (68.4,81.7) | 53.1 (45.3,60.7) | 38.7 (31.4,46.4) | 2.7 (2.2–3.5) | < 0.001 |
UKA= unicompartmental knee arthroplasty; (years); * number of revisions/number of total operations; **survivorship obtained via Kaplan-Meier analysis.hazard ratio (HR) according to Cox proportional hazards model (adjusted by sex and age); Oxford®, Biomet Inc, Warsaw, IN, USA; Miller-Galante, Zimmer, Warsaw, IN, USA; Duracon™, Stryker, Mahwah, NJ, USA; Porous Coated Anatomic (PCA®), Howmedica, Rutherford, NJ, USA.